10 . 10 .2019
Press release
Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis
09 . 10 .2019
Press release
Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility
07 . 10 .2019
Press release
Galderma Receives FDA Approval for AKLIEF® (trifarotene) Cream, 0.005%, the First New Retinoid Molecule for the Treatment of Acne in Over 20 Years
02 . 10 .2019
Press release
Galderma to become the world’s largest independent global dermatology company after completion of CHF 10.2 billion carve-out of Nestlé Skin Health
16 . 05 .2019
Press release
Nestlé enters into exclusive negotiations to sell Nestlé Skin Health to a consortium led by EQT and ADIA
08 . 04 .2019
Press release
Galderma marks Rosacea Awareness Month with new insights into why some patients are self-treating and launches social media campaign to reinforce hidden impact of the disease
06 . 04 .2019
Press release
Galderma´s Azzalure and Dysport® celebrate a decade of treatment of the glabellar lines
08 . 03 .2019
Press release
Galderma Presented Final Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis at the 2019 American Academy of Dermatology Annual Meeting Late-Breaking Session